Company Description
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.
The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency.
The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products.
Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2006 |
| IPO Date | Mar 28, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Michael Amoroso |
Contact Details
Address: 302 East Pettigrew Street, Suite A-100 Durham, North Carolina 27701 United States | |
| Phone | 919 314 5512 |
| Website | precisionbiosciences.com |
Stock Details
| Ticker Symbol | DTIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001357874 |
| CUSIP Number | 74019P108 |
| ISIN Number | US74019P2074 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Naresh Tanna | Chief of Staff to Chief Executive Officer and Head of Investor Relations |
| Michael Amoroso | President, Chief Executive Officer and Director |
| John Alexander Kelly R.Ph. | Chief Financial Officer and Principal Accounting Officer |
| Dr. Jefferson J. Smith Ph.D. | Co-Founder and Chief Research Officer |
| Bruce Stevens | Vice President of Quality and Compliance |
| Maurissa Messier | Senior Director of Corporate Communications |
| Juli Blanche | Chief People Officer |
| Garrett Gincley | Head of Manufacturing |
| Cindy Atwell | Chief Business Officer |
| Neil Leatherbury M.S. | Senior Vice President and Head of Chemistry, Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | 144 | Filing |
| Nov 4, 2024 | 144 | Filing |
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 8-K | Current Report |